Ad
related to: pertuzumab and trastuzumab neoadjuvant cancer- Safety Information
Access Clinical Safety Info
Keep Current On News For Physicians
- Request More Information
Be The First To Get Updates
And News About TUKYSA®
- Request A Call Today
Get Updates, Resources & More
Information About TUKYSA®
- Download Resources
For Healthcare Professionals
About A Treatment Option
- Safety Information
Search results
Results from the WOW.Com Content Network
Pertuzumab is administered as an intravenous infusion in combination with trastuzumab and docetaxel as a first line treatment for HER2-positive metastatic breast cancer. [4] [3] It is also used in the same combination as a neoadjuvant (given to reduce the size of a tumor, prior to surgery or radiation) for HER2-positive early breast cancer; as of 2016 this use had not been shown to increase ...
The fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase was approved for medical use in the United States in June 2020. [5] [10]The FDA's approval was based on the results of a non-inferiority study in participants with HER2-positive early breast cancer, which demonstrated the fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase had comparable efficacy and ...
In the advanced cancer setting, trastuzumab use in combination with chemotherapy can both delay cancer growth as well as improve the recipient's survival. [49] Pertuzumab may work synergistically with trastuzumab on the expanded EGFR family of receptors, although it is currently only standard of care for metastatic disease.
In 2013, trastuzumab emtansine was approved in the UK, [4] and the EU. [6] In 2019, trastuzumab emtansine was approved in the United States for the adjuvant treatment of patients with HER2-positive early breast cancer (EBC) who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. [24]
Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. [ 30 ] [ 27 ] [ 31 ] [ 32 ] It is specifically used for cancer that is HER2 receptor positive . [ 30 ]
Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the topoisomerase I inhibitor deruxtecan (a derivative of exatecan). [11] [12] It is licensed for the treatment of breast cancer or gastric or gastroesophageal ...
Clinical trial number NCT01566721 for "A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer (SafeHER)" at ClinicalTrials.gov
Neoadjuvant chemotherapy is given before surgery to slow the growth of a fast-growing cancer or to shrink the size of a larger breast cancer. [ 1 ] It is frequently used to treat locally advanced cancers, cancers that at the time of diagnosis are too large to be removed by surgery, which can then be removed with less extensive surgery.
Ad
related to: pertuzumab and trastuzumab neoadjuvant cancer